Dysregulation of the C/EBPa Pathway in Human Lung Cancer and Search for New Biomarkers and/or Therapeutic Targets

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01619501
Recruitment Status : Unknown
Verified December 2013 by National University Hospital, Singapore.
Recruitment status was:  Recruiting
First Posted : June 14, 2012
Last Update Posted : December 11, 2013
Information provided by (Responsible Party):
National University Hospital, Singapore

Brief Summary:

The overall goal of this research is to enhance the investigators understanding of the pathways involved in lung cancer, and to identify new biomarkers and/or therapeutic targets. By comparing gene expression between normal lung tissue and tumors growing in lung-specific C/EBPa KO mice, the investigators have identified the Bmi-1 proto-oncogene as being abnormally upregulated in C/EBPa-deleted tumors. Subsequently, the investigators have validated this observation in human lung cancer, implicating the investigators KO mice are an effective discovery tool for lung cancer research. Through similar approaches, the investigators have already identified (Sonic Hedgehog, SHH), and plan to identify other pathways which are abnormally regulated in C/EBPa-/- tumors. In parallel, the investigators will proceed to define the clinical relevance of the SHH pathway and the other newly-discovered molecular aberrations, by analyzing their expression and correlate it to C/EBPa expression on the samples of patients with NSCLC at NUHS. If the investigators preliminary data on Bmi-1 will be confirmed, this proto-oncogene may generate useful correlates that could be used in diagnosis and treatment of lung cancer, as well as identify new prognostic/predictive markers in lung cancer. Similarly, SHH pathway-components may behave as potential biomarkers and therapeutic tools for C/EBPa-related lung cancers.

This proposal seeks to test the hypothesis that pathways which are dysregulated in lung tumors growing in a lung-specific C/EBPa KO model can be utilized as discovery tools to identify genes involved in human lung cancer pathogenesis.

Condition or disease
Lung Cancer

Study Type : Observational
Observational Model: Cohort
Time Perspective: Retrospective
Study Start Date : April 2012
Estimated Primary Completion Date : March 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Cancer

Primary Outcome Measures :
  1. Define the C/EBPa-Bmi-1 axis in human lung cancer
    Tissue microarrays will be created from the lung tumours. Only resection specimens will be used for TMA construction, and small, limited biopsies will not be used. Tissue punches of 1.5mm in diameter will be cut from the blocks (2 punches per tumour, 1 punch for normal lung). Hence the rest of the tumour block is not used, preserving most of the tumour tissue in the tissue blocks, for future diagnostic use.

Secondary Outcome Measures :
  1. Validate the relevance of the C/EBPa-SHH pathway in human NSCLC
    We will stain the human lung cancer specimens with antibodies against Gli1 (the major effector of the SHH pathway), Patched-1, Patched-2 and Smoothened (the receptors of the pathway), Sonic, Indian and Desert Hedgehog (the ligands of the pathway), and Cyclin D, Cyclin E, and Myc (target genes of the pathway).Interestingly, the SHH pathway has been recently associated to primary cilia (PC), where its specific role is highly controversial. Genetic defects affecting PC result in a myriad of pathological instances, including lung pathologies

  2. Identify new downstream targets of C/EBPa in murine lung cancer and test their involvement in human pathogenesis
    RNA microarray analysis will be performed by Dr. Levantini at the BIDMC (Tenen lab, Boston), to compare gene expression between C/EBPa-/- pulmonary tumors and the neighboring normal murine tissue. The mouse MOE430A gene chip from Affymetrix will be utilized, as recently published (Basseres et al., MCB 2006). Single cell suspension will be depleted by FACS for endothelial and hematopoietic markers (CD45, Ter119, CD31). Purified populations will then undergo cRNA synthesis followed by hybridization to the Affymetrix gene chips. The top 10,000 genes will be selected based on their ranking.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Archived samples from the Department of Pathology (for IHC, FISH) and the Tissue Repository (for fresh tumor samples) at NUHS

Inclusion Criteria:

Patients with lung cancer

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01619501

Contact: Ross Soo +65 6779 5555

Nationa University Hospital Recruiting
Singapore, Singapore
Contact: Ross Soo    +65 6779 5555      
Principal Investigator: Ross Soo         
Sponsors and Collaborators
National University Hospital, Singapore

Responsible Party: National University Hospital, Singapore Identifier: NCT01619501     History of Changes
Other Study ID Numbers: 2012/00117
First Posted: June 14, 2012    Key Record Dates
Last Update Posted: December 11, 2013
Last Verified: December 2013

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases